Your browser is no longer supported. Please, upgrade your browser.
Settings
SYBX Synlogic, Inc. daily Stock Chart
SYBX [NASD]
Synlogic, Inc.
Index- P/E- EPS (ttm)-2.00 Insider Own0.20% Shs Outstand25.56M Perf Week21.96%
Market Cap197.32M Forward P/E- EPS next Y-2.34 Insider Trans- Shs Float24.34M Perf Month-6.54%
Income-50.20M PEG- EPS next Q-0.52 Inst Own82.90% Short Float4.71% Perf Quarter-1.40%
Sales2.50M P/S78.93 EPS this Y18.30% Inst Trans0.68% Short Ratio10.39 Perf Half Y1.05%
Book/sh4.44 P/B1.74 EPS next Y-8.80% ROA-33.60% Target Price19.56 Perf Year-17.52%
Cash/sh4.30 P/C1.80 EPS next 5Y- ROE-38.90% 52W Range5.75 - 14.59 Perf YTD10.13%
Dividend- P/FCF- EPS past 5Y7.90% ROI-41.10% 52W High-47.09% Beta2.29
Dividend %- Quick Ratio11.50 Sales past 5Y- Gross Margin- 52W Low34.26% ATR0.63
Employees74 Current Ratio11.50 Sales Q/Q-25.00% Oper. Margin- RSI (14)51.18 Volatility9.15% 7.36%
OptionableNo Debt/Eq0.00 EPS Q/Q7.60% Profit Margin- Rel Volume2.14 Prev Close7.77
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume110.37K Price7.72
Recom1.30 SMA201.07% SMA50-2.86% SMA200-12.14% Volume230,683 Change-0.64%
Apr-30-19Initiated Jefferies Buy $18
Dec-13-18Initiated Chardan Capital Markets Buy $20
Mar-19-18Initiated H.C. Wainwright Buy $20
Jan-29-18Initiated Piper Jaffray Overweight $16
Jun-12-19 06:30AM  Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic Medicines Business Wire +25.20%
May-23-19 04:15PM  Synlogic (SYBX) Enters Cancer Collaboration with Roche Zacks
May-22-19 07:00AM  Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors Business Wire
May-16-19 09:14PM  Synlogic, Inc. (SYBX) Q1 2019 Earnings Call Transcript Motley Fool
May-15-19 01:12PM  Edited Transcript of SYBX earnings conference call or presentation 9-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-09-19 04:02PM  Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire
May-02-19 04:05PM  Synlogic Announces First Quarter 2019 Conference Call and Webcast Business Wire -8.12%
Apr-30-19 07:00AM  Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic Medicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) Business Wire +10.85%
Apr-26-19 04:26PM  Gut Check: The Bacteria In Your Intestines Could Help Cure Cancer Investor's Business Daily
11:43AM  Could Synlogic, Inc.'s (NASDAQ:SYBX) Investor Composition Influence The Stock Price? Simply Wall St.
Apr-15-19 04:10PM  Synlogic to Present Data from New Solid Oral Formulation Process at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) Business Wire
Apr-09-19 07:00AM  Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer Business Wire
Apr-02-19 04:05PM  Synlogic to Webcast Presentation at the 18th Annual Needham Healthcare Conference Business Wire
Mar-18-19 11:41AM  Edited Transcript of SYBX earnings conference call or presentation 12-Mar-19 12:00pm GMT Thomson Reuters StreetEvents
Mar-13-19 04:05PM  Synlogic to Webcast Presentation at the Oppenheimer 29th Annual Healthcare Conference Business Wire
Mar-12-19 07:00AM  Synlogic Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update Business Wire -7.86%
Mar-06-19 07:00AM  Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic Medicines to Treat Inflammatory Bowel Disease Business Wire -6.87%
Mar-05-19 04:05PM  Synlogic Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast Business Wire
Feb-28-19 05:00PM  Synlogic to Present at Investor Conferences in March Business Wire
Feb-20-19 04:02PM  Synlogic to Webcast Presentation at the SVB Leerink 8th Annual Global Healthcare Conference Business Wire
Feb-12-19 07:00AM  Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of Directors Business Wire +7.30%
Jan-16-19 02:01PM  Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogics Synthetic Biotic Medicine in Development as a Potential Treatment for Hyperammonemia Business Wire
Jan-03-19 08:00AM  Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2019 Catalysts Business Wire
Dec-12-18 07:00AM  Synlogic Expands Capabilities in Manufacturing with the Appointment of Head of Technical Operations and Establishment of In-house Production of Clinical Trial Material for its Synthetic BioticTM Medicines Business Wire
Nov-23-18 08:50AM  Research Report Identifies Synlogic, Consolidated Water Co., AeroCentury, Tecogen, Truett-Hurst, and Marchex with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-20-18 04:05PM  Synlogic to Webcast Presentation at the 30th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-13-18 04:05PM  Synlogic Reports Third Quarter 2018 Financial Results and Provides Program Updates Business Wire
Nov-12-18 04:23PM  Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) Business Wire
Nov-07-18 04:20PM  Synlogic Announces Third Quarter 2018 Conference Call and Webcast Business Wire
Nov-06-18 08:01AM  Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancers (SITC) 33rd Annual Meeting Business Wire
Nov-05-18 10:30AM  Will Synlogic, Inc (SYBX) Report Negative Earnings Next Week? What You Should Know Zacks
Nov-01-18 04:05PM  Synlogic to Host Analyst & Investor Event at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting Business Wire +5.18%
Oct-02-18 07:00AM  Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer Business Wire
Sep-25-18 04:05PM  Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology Business Wire
07:30AM  Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors Business Wire
Sep-05-18 03:20PM  How This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic Disease Investor's Business Daily +18.92%
Sep-04-18 02:30AM  Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU) Business Wire
Aug-29-18 04:05PM  Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference Business Wire
Aug-16-18 06:29AM  Synlogic data shows reduction in disability-causing disease in mice American City Business Journals
Aug-13-18 11:16AM  Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic Medicine as a Potential Treatment for Phenylketonuria Business Wire
Aug-08-18 04:02PM  Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates Business Wire -5.98%
Aug-07-18 04:02PM  Synlogic to Webcast Presentation at the 2018 Wedbush PacGrow Healthcare Conference Business Wire
Jun-25-18 07:10AM  Synlogic Presents New Preclinical Data from Synthetic Biotic Immuno-Oncology Program at FOCIS 2018 Business Wire -8.45%
07:00AM  Synlogic Joins Russell 3000® Index Business Wire
Jun-11-18 04:02PM  Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria Business Wire
Jun-05-18 09:00AM  Why Synlogic (SYBX) Could Be a Potential Winner Zacks
Jun-04-18 07:00AM  Synlogic Presents New Preclinical Data from Synthetic Biotic Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week® Business Wire
May-24-18 07:38AM  Synlogic (SYBX) Enters Oversold Territory Zacks -5.03%
May-15-18 07:00AM  Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update Business Wire
May-10-18 04:10PM  Synlogic Announces Leadership Change Business Wire
Apr-25-18 07:00AM  Synlogic Receives Fast-Track Designation for SYNB1618, a Synthetic Biotic medicine for the Treatment of Phenylketonuria Business Wire
Apr-18-18 07:00AM  Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of Phenylketonuria Business Wire
Apr-16-18 04:02PM  Synlogic Presents Preclinical Data from Synthetic Biotic Immuno-Oncology Program at the American Association for Cancer Research 2018 Annual Meeting Business Wire
Apr-06-18 08:30AM  Synlogic Announces Registered Direct Offering of Common Stock Business Wire +5.66%
Apr-04-18 07:10AM  Wired News Synlogic Announced First Subject Dosed in Phase-1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis ACCESSWIRE
Apr-02-18 07:00AM  Synlogic Doses First Patient in Phase 1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis Business Wire
Mar-21-18 04:05PM  Synlogic to Present at the 17th Annual Needham Healthcare Conference Business Wire +5.46%
Mar-20-18 04:51PM  Mirna Therapeutics reports 4Q loss Associated Press
04:02PM  Synlogic Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update Business Wire
Mar-19-18 04:16PM  Synlogic to Present Data at the American Association for Cancer Research 2018 Annual Meeting Business Wire
08:39AM  Why Synlogic (SYBX) Might Surprise This Earnings Season Zacks
Mar-12-18 07:00AM  Synlogic Presents Clinical and Preclinical Data from Synthetic Biotic Medicine Programs for Treatment of Inborn Errors of Metabolism at Annual Meeting of The Society for Inherited Metabolic Disorders Business Wire -8.61%
Mar-05-18 04:05PM  Synlogic to Webcast Presentation at the Cowen and Company 38th Annual Health Care Conference Business Wire
Feb-20-18 08:00AM  Changes to its Board of Directors: Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industry Marketwired
Feb-13-18 08:00AM  Synlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity Following Administration of Novel STING Agonist-producing Synthetic Biotic Medicine Business Wire
Feb-08-18 04:05PM  Synlogic to Present at the Leerink Partners 7th Annual Global Healthcare Conference Business Wire
Jan-31-18 04:05PM  Synlogic Announces Underwriters Option Exercise in Full Business Wire
08:30AM  New Analyst Coverage Puts the Spotlight on These 5 Stocks Zacks
Jan-24-18 08:14AM  Synlogic Announces Pricing of Public Offering of Common Stock Business Wire -9.43%
Jan-23-18 04:01PM  Synlogic Announces Proposed Public Offering of Common Stock Business Wire
Jan-05-18 08:00AM  Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2018 Catalysts Business Wire
Dec-11-17 07:30AM  Blog Exposure - Synlogic And Ginkgo Bioworks Collaborate to Discover and Develop New Medicines for Neurological and Liver Disorders ACCESSWIRE
Dec-08-17 06:00AM  Synlogic and Ginkgo Bioworks Announce Collaboration as First Step Toward Building an Unprecedented Discovery Engine for Novel Living Medicines in Neurological and Liver Disorders Business Wire +5.85%
Nov-13-17 04:05PM  Synlogic Reports Third Quarter 2017 Financial Results and Recent Progress Business Wire -9.91%
Nov-08-17 04:05PM  Synlogic to Present at Upcoming Investor Conferences in November Business Wire
08:00AM  Synlogic Reports Positive Top-Line Phase 1 Data Demonstrating Safety and Tolerability and Proof of Mechanism in Healthy Volunteers for SYNB1020, a Synthetic BioticTM Medicine for the Treatment of Hyperammonemia Business Wire
Oct-24-17 08:30AM  Synlogic Receives Orphan Drug Designation for SYNB1618, a Synthetic BioticTM Medicine for the Treatment of Phenylketonuria Business Wire
Oct-10-17 08:30AM  Synlogic Strengthens Leadership Team with Appointment of Chief Operating Officer and Chief Human Resources Officer Business Wire
Sep-20-17 04:05PM  Synlogic to Webcast Presentation at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology Business Wire
Sep-07-17 08:30AM  Synlogic Presents New Preclinical Data at International Congress of Inborn Errors of Metabolism Business Wire +8.37%
Sep-01-17 08:30AM  Synlogic to Webcast Presentation at BioCenturys 24th Annual NewsMakers in the Biotech Industry Conference Business Wire
Aug-28-17 09:15AM  Synlogic Completes Merger with Mirna Therapeutics Business Wire
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.a.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.